Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Indivior PLC
  6. News
  7. Summary
    INDV   GB00BRS65X63

INDIVIOR PLC

(INDV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Scopia Capital Management To Sell 3% Stake In Indivior

11/09/2021 | 11:36pm EST


ę MT Newswires 2021
All news about INDIVIOR PLC
01/12FDA flags risk of dental issues from use of opioid addiction drug buprenorphine
RE
2021Biogen V. Mylan Written Description - What Does The Federal Circuit's Decision Really M..
AQ
2021INDIVIOR : to Present New Data on Buprenorphine Extended-Release at the 2021 Joint Interna..
PU
2021INDIVIOR : Financial Document
PU
2021Scopia Capital Sells 3% Stake In Indivior
MT
2021Scopia Capital Management To Sell 3% Stake In Indivior
MT
2021Indivior Presents Modelling Data on Interaction Between Buprenorphine and Fentanyl in O..
PU
2021Indivior to Participate in Upcoming November 2021 Healthcare Investor Conferences
PU
2021Indivior Presents Study at the 2021 National Correctional Health Care Conference on Fac..
PU
2021Indivior's Lifts FY21 Net Revenue Guidance As Q3 Earnings Rise
MT
More news
Analyst Recommendations on INDIVIOR PLC
More recommendations
Financials (USD)
Sales 2021 758 M - -
Net income 2021 159 M - -
Net cash 2021 708 M - -
P/E ratio 2021 16,3x
Yield 2021 -
Capitalization 2 291 M 2 300 M -
EV / Sales 2021 2,09x
EV / Sales 2022 1,86x
Nbr of Employees 788
Free-Float 98,8%
Chart INDIVIOR PLC
Duration : Period :
Indivior PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,26 $
Average target price 4,11 $
Spread / Average Target 26,0%
EPS Revisions
Managers and Directors
Mark Crossley Executive Director, CEO & COO
Ryan Preblick Chief Financial Officer & Executive Director
Graham C. Hetherington Chairman
Christian Heidbreder Chief Scientific Officer
Cynthia Cetani Chief Compliance & Integrity Officer
Sector and Competitors
1st jan.Capi. (M$)
INDIVIOR PLC-6.61%2 218
MERCK KGAA-16.30%93 755
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-11.47%37 178
KYOWA KIRIN CO. LTD.-9.44%13 352
SK BIOPHARMACEUTICALS CO., LTD.-11.52%5 612
BETTA PHARMACEUTICALS CO., LTD.-10.94%4 893